RTP-based Tranzyme, Inc. (www.tranzyme.com) has extended its collaborative agreement with Massachusetts-based NeoGenesis Pharmaceuticals to include additional genes of therapeutic interest. The collaboration will continue in the areas of gene expression and drug discovery and will utilize Tranzyme's “TexT” (Tranz Expression Technology) in support of the chemical genomics program at NeoGenesis. The two companies entered into their original collaboration in August 2001.
To date, Tranzyme has engineered over 50 mammalian cell lines expressing important therapeutic targets for drug discovery applications including cancer, viral diseases, CNS disorders, and metabolic diseases. Under the expanded collaboration, NeoGenesis will provide additional sets of disease-associated gene sequences of therapeutic interest. Tranzyme will deliver these genes into different mammalian cell lines and express the proteins using its protein expression technology, according to company reports.
Tranzyme is a CED member.